Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 22–23
HOS-086330 · Präparat HOS-083284
22
Ritonavir effects on Non-antiretroviral Co-administered Medicinal Products
Co-administered Medicinal Products Dose of Co- Dose of Effect on Co- Effect on Co-
administered NORVIR (mg) administered administered
Medicinal Products Medicinal Medicinal Products
(mg) Products Cmax
AUC
Steroids
Inhaled, injectable or intranasal Systemic corticosteroid effects including Cushing's syndrome and adrenal
fluticasone propionate, budesonide, suppression (plasma cortisol levels were noted to be decreased 86% in the above
triamcinolone study) have been reported in patients receiving ritonavir and inhaled or intranasal
fluticasone propionate; similar effects could also occur with other corticosteroids
metabolised by CYP3A e.g., budesonide and triamcinolone. Consequently,
concomitant administration of ritonavir dosed as an antiretroviral agent or as a
pharmacokinetic enhancer and these glucocorticoids is not recommended unless the
potential benefit of treatment outweighs the risk of systemic corticosteroid effects
(see section 4.4). A dose reduction of the glucocorticoid should be considered with
close monitoring of local and systemic effects or a switch to a glucocorticoid, which
is not a substrate for CYP3A4 (e.g., beclomethasone). Moreover, in case of
withdrawal of glucocorticoids progressive dose reduction may be required over a
longer period.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triamcinolone (HOS-086333) fluticasone propionate (HOS-086331) budesonide (HOS-086332) beclomethasone (HOS-086334)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage e821932a6386211f79b6dab6d650a9f78b32c891ab2c668342b27fcfb35a4407 · Zeichen 56091–58213 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 55–56
HOS-086491 · Präparat HOS-083284
55
Ritonavir effects on Non-antiretroviral Co-administered Medicinal Products
Co-administered Medicinal Products Dose of Co-administered Medicinal Dose of Effect on Co- Effect on Co-
Products (mg) NORVIR administered administered
(mg) Medicinal Medicinal
Products Products Cmax
AUC
beclomethasone). Moreover, in case of withdrawal of glucocorticoids progressive dose
reduction may be required over a longer period.
Dexamethasone Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits
CYP3A and as a result is expected to increase the plasma concentrations of
dexamethasone. Careful monitoring of therapeutic and adverse effects is recommended
when dexamethasone is concomitantly administered with ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535) beclomethasone (HOS-086334)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 583c78782a662f698dfa7073351d7e54382050be74d07dd6c457adfd36e23bc8 · Zeichen 59772–61113 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 21–22
HOS-108912 · Präparat HOS-093083
21
Inhaled, injectable or Fluticasone propionate, 50 g Greater effects may be expected
intranasal fluticasone intranasal 4 times daily: when fluticasone propionate is
propionate, budesonide, Plasma concentrations ↑ inhaled. Systemic corticosteroid
triamcinolone Cortisol levels ↓ 86% effects including Cushing's
syndrome and adrenal suppression
have been reported in patients
receiving ritonavir and inhaled or
intranasally administered
fluticasone propionate; this could
also occur with other
corticosteroids metabolised via the
P450 3A pathway e.g. budesonide
and triamcinolone. Consequently,
concomitant administration of
Kaletra and these glucocorticoids
is not recommended unless the
potential benefit of treatment
outweighs the risk of systemic
corticosteroid effects (see section
4.4). A dose reduction of the
glucocorticoid should be
considered with close monitoring
of local and systemic effects or a
switch to a glucocorticoid, which
is not a substrate for CYP3A4 (e.g.
beclomethasone). Moreover, in
case of withdrawal of
glucocorticoids progressive dose
reduction may have to be
performed over a longer period.
Phosphodiesterase(PDE5) inhibitors
Avanafil Avanafil: The use of avanafil with Kaletra is
(ritonavir 600 mg BID) AUC: ↑ 13-fold contraindicated (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triamcinolone (HOS-086333) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) avanafil (HOS-086161) budesonide (HOS-086332) propionate (HOS-108915) beclomethasone (HOS-086334)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 95f7b89617dc0d65066440c9865de8ccb96b79023be5509ed30cc6b686a9782e · Zeichen 45456–48489 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 57–58
HOS-109017 · Präparat HOS-093083
57
Inhaled, injectable or Fluticasone propionate, 50 g Greater effects may be expected
intranasal fluticasone intranasal 4 times daily: when fluticasone propionate is
propionate, budesonide, Plasma concentrations ↑ inhaled. Systemic corticosteroid
triamcinolone Cortisol levels ↓ 86% effects including Cushing's syndrome
and adrenal suppression have been
reported in patients receiving
ritonavir and inhaled or intranasally
administered fluticasone propionate;
this could also occur with other
corticosteroids metabolised via the
P450 3A pathway e.g. budesonide
and triamcinolone. Consequently,
concomitant administration of Kaletra
and these glucocorticoids is not
recommended unless the potential
benefit of treatment outweighs the
risk of systemic corticosteroid effects
(see section 4.4). A dose reduction of
the glucocorticoid should be
considered with close monitoring of
local and systemic effects or a switch
to a glucocorticoid, which is not a
substrate for CYP3A4 (e.g.
beclomethasone). Moreover, in case
of withdrawal of glucocorticoids
progressive dose reduction may have
to be performed over a longer period.
Phosphodiesterase(PDE5) inhibitors
Avanafil Avanafil: The use of avanafil with Kaletra is
(ritonavir 600 mg BID) AUC: ↑ 13-fold contraindicated (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir.
Tadalafil Tadalafil: For the treatment of pulmonary
AUC: ↑ 2-fold arterial hypertension:
Due to CYP3A4 inhibition by Co-administration of Kaletra with
lopinavir/ritonavir. sildenafil is contraindicated (see
Sildenafil Sildenafil: section 4.3). Co-administration of
AUC: ↑ 11-fold Kaletra with tadalafil is not
Due to CYP3A inhibition by recommended.
lopinavir/ritonavir.
For erectile dysfunction:
Particular caution must be used when
prescribing sildenafil or tadalafil in
patients receiving Kaletra with
increased monitoring for adverse
events including hypotension,
syncope, visual changes and
prolonged erection (see section 4.4).
When co-administered with Kaletra,
sildenafil doses must not exceed
25 mg in 48 hours and tadalafil doses
must not exceed 10 mg every 72
hours.
Vardenafil Vardenafil: The use of vardenafil with Kaletra is
AUC: ↑ 49-fold contraindicated (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triamcinolone (HOS-086333) tadalafil (HOS-086316) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) avanafil (HOS-086161) budesonide (HOS-086332) propionate (HOS-108915) sildenafil (HOS-086162) beclomethasone (HOS-086334) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 51c234e1918855f44c1bb972e14fc32ef0403c1dd2140c6f4cb763ba5bcc0839 · Zeichen 44014–48937 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 92–93
HOS-109093 · Präparat HOS-093083
92
Inhaled, injectable or Fluticasone propionate, 50 g Greater effects may be expected
intranasal fluticasone intranasal 4 times daily: when fluticasone propionate is
propionate, budesonide, Plasma concentrations ↑ inhaled. Systemic corticosteroid
triamcinolone Cortisol levels ↓ 86% effects including Cushing's
syndrome and adrenal suppression
have been reported in patients
receiving ritonavir and inhaled or
intranasally administered
fluticasone propionate; this could
also occur with other corticosteroids
metabolised via the P450 3A
pathway e.g. budesonide and
triamcinolone. Consequently,
concomitant administration of
Kaletra and these glucocorticoids is
not recommended unless the
potential benefit of treatment
outweighs the risk of systemic
corticosteroid effects (see section
4.4). A dose reduction of the
glucocorticoid should be considered
with close monitoring of local and
systemic effects or a switch to a
glucocorticoid, which is not a
substrate for CYP3A4 (e.g.
beclomethasone). Moreover, in
case of withdrawal of
glucocorticoids progressive dose
reduction may have to be performed
over a longer period.
Phosphodiesterase(PDE5) inhibitors
Avanafil Avanafil: The use of avanafil with Kaletra is
(ritonavir 600 mg BID) AUC: ↑ 13-fold contraindicated (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): triamcinolone (HOS-086333) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) avanafil (HOS-086161) budesonide (HOS-086332) propionate (HOS-108915) beclomethasone (HOS-086334)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 497011109bf2b2d1a0b56b0819ad55285ecfc4baf550264239853c107df5ec09 · Zeichen 44865–47860 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 20–21
HOS-112108 · Präparat HOS-093615
20
Medicinal products by Interaction Recommendations concerning co-
therapeutic area administration
Fluticasone propionate The fluticasone propionate plasma levels Co-administration of
intranasal 50 μg 4 times daily increased significantly, whereas the REYATAZ/ritonavir and these
for 7 days intrinsic cortisol levels decreased by glucocorticoids metabolised by
(ritonavir 100 mg capsules twice approximately 86% (90% confidence CYP3A4 is not recommended
daily) interval 82%-89%). Greater effects may be unless the potential benefit of
expected when fluticasone propionate is treatment outweighs the risk of
And inhaled. Systemic corticosteroid effects systemic corticosteroid effects
including Cushing’s syndrome and adrenal (see section 4.4).
Inhaled/Nasal Corticosteroids suppression have been reported in patients A dose reduction of the
receiving ritonavir and inhaled or glucocorticoid should be considered
intranasally administered fluticasone with close monitoring of local and
propionate; this could also occur with systemic effects or a switch to a
other corticosteroids metabolised via the glucocorticoid, which is not a
P450 3A pathway, e.g., budesonide. The substrate for CYP3A4 (e.g.,
effects of high fluticasone systemic beclomethasone). Moreover, in case
exposure on ritonavir plasma levels are yet of withdrawal of glucocorticoids,
unknown. The mechanism of interaction is progressive dose reduction may
CYP3A4 inhibition. have to be performed over a longer
period.
Concomitant use of REYATAZ (with or
without ritonavir) and other Inhaled/Nasal Concomitant use of Inhaled/Nasal
Corticosteroids is expected to produce the Corticosteroids and REYATAZ
same effects. (with or without ritonavir) may
increase plasma concentrations of
Inhaled/Nasal corticosteroids. Use
with caution. Consider alternatives
to Inhaled/Nasal Corticosteroids,
particularly for long-term use.
ERECTILE DYSFUNCTION
PDE5 Inhibitors
Sildenafil, tadalafil, vardenafil Sildenafil, tadalafil, and vardenafil are
Patients should be warned about
metabolised by CYP3A4. Co- these possible side effects when
administration with REYATAZ may result
using PDE5 inhibitors for erectile
in increased concentrations of the PDE5
dysfunction with REYATAZ (see
inhibitor and an increase in PDE5-
section 4.4).
Also see PULMONARY
associated adverse events, including
ARTERIAL HYPERTENSION in
hypotension, visual changes, and priapism.
this table for further information
The mechanism of this interaction is
CYP3A4 inhibition. regarding co-administration of
REYATAZ with sildenafil.
GONADOTROPIN-RELEASING HORMONE (GnRH) RECEPTOR ANTAGONISTS
Elagolix The mechanism of interaction is Concomitant use of elagolix
anticipated increase in elagolix exposure in 200 mg twice daily with
the presence of CYP3A4 inhibition by REYATAZ (with or without
atazanavir and/or ritonavir. ritonavir) for more than 1 month is
not recommended due to the
potential risk of adverse events
such as bone loss and hepatic
transaminase elevations. Limit
concomitant use of elagolix 150 mg
once daily with REYATAZ (with
or without ritonavir) to 6 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) elagolix (HOS-112109) budesonide (HOS-086332) propionate (HOS-108915) sildenafil (HOS-086162) ritonavir (HOS-084521) beclomethasone (HOS-086334) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 635c8268586ef0a6549f4f61ffc231edde0b1b51942c8c61e4e49a8f50290b2a · Zeichen 55637–61614 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 56–57
HOS-112197 · Präparat HOS-093615
56
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
Fluticasone propionate The fluticasone propionate plasma levels Co-administration of
intranasal 50 μg 4 times daily increased significantly, whereas the REYATAZ/ritonavir and these
for 7 days intrinsic cortisol levels decreased by glucocorticoids metabolised by
(ritonavir 100 mg capsules approximately 86% (90% confidence CYP3A4 is not recommended
twice daily) interval 82%-89%). Greater effects may be unless the potential benefit of
expected when fluticasone propionate is treatment outweighs the risk of
And inhaled. Systemic corticosteroid effects systemic corticosteroid effects
including Cushing’s syndrome and adrenal (see section 4.4).
Inhaled/Nasal Corticosteroids suppression have been reported in patients A dose reduction of the
receiving ritonavir and inhaled or glucocorticoid should be
intranasally administered fluticasone considered with close
propionate; this could also occur with other monitoring of local and
corticosteroids metabolised via the P450 systemic effects or a switch to
3A pathway, e.g., budesonide. The effects a glucocorticoid, which is not a
of high fluticasone systemic exposure on substrate for CYP3A4 (e.g.,
ritonavir plasma levels are yet unknown. beclomethasone). Moreover, in
The mechanism of interaction is CYP3A4 case of withdrawal of
inhibition. glucocorticoids, progressive
dose reduction may have to be
Concomitant use of REYATAZ (with or performed over a longer
without ritonavir) and other Inhaled/Nasal period.
Corticosteroids is expected to produce the
same effects. Concomitant use of
Inhaled/Nasal Corticosteroids
and REYATAZ (with or
without ritonavir) may increase
plasma concentrations of
Inhaled/Nasal corticosteroids.
Use with caution. Consider
alternatives to Inhaled/Nasal
Corticosteroids, particularly for
long-term use.
ERECTILE DYSFUNCTION
PDE5 Inhibitors
Sildenafil, tadalafil, Sildenafil, tadalafil, and vardenafil are
Patients should be warned
vardenafil metabolised by CYP3A4. Co- about these possible side
administration with REYATAZ may result
effects when using PDE5
in increased concentrations of the PDE5
inhibitors for erectile
inhibitor and an increase in PDE5-
dysfunction with REYATAZ
associated adverse events, including
(see section 4.4).
Also see PULMONARY
hypotension, visual changes, and priapism.
ARTERIAL
The mechanism of this interaction is
CYP3A4 inhibition. HYPERTENSION in this table
for further information
regarding co-administration of
REYATAZ with sildenafil.
GONADOTROPIN-RELEASING HORMONE (GnRH) RECEPTOR ANTAGONISTS
Elagolix The mechanism of interaction is anticipated Concomitant use of elagolix
increase in elagolix exposure in the 200 mg twice daily with
presence of CYP3A4 inhibition by REYATAZ (with or without
atazanavir and/or ritonavir. ritonavir) for more than
1 month is not recommended
due to the potential risk of
adverse events such as bone
loss and hepatic transaminase
elevations. Limit concomitant
use of elagolix 150 mg once
daily with REYATAZ (with or
without ritonavir) to 6 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) elagolix (HOS-112109) budesonide (HOS-086332) propionate (HOS-108915) sildenafil (HOS-086162) ritonavir (HOS-084521) beclomethasone (HOS-086334) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 48a34194fe14fdb331f424e7223a33e7800beb55222a98a47e4c5a5060800d73 · Zeichen 57743–64096 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 22–23
HOS-114854 · Präparat HOS-094169
22
Bupropion 150 mg BID Bupropion Cmax ↓ 51% If the co-administration with
Bupropion AUC ↓ 56% bupropion is judged unavoidable,
this should be done under close
Tipranavir ↔ clinical monitoring for bupropion
efficacy, without exceeding the
The reduction of bupropion recommended dosage, despite the
plasma levels is likely due to observed induction.
induction of CYP2B6 and UGT
activity by RTV
Loperamide 16 mg QD Loperamide Cmax ↓ 61% A pharmacodynamic interaction
Loperamide AUC ↓ 51% study in healthy volunteers
demonstrated that administration
Mechanism unknown of loperamide and Aptivus, co-
administered with low dose
Tipranavir Cmax ↔ ritonavir, does not cause any
Tipranavir AUC ↔ clinically relevant change in the
Tipranavir Cmin ↓ 26% respiratory response to carbon
dioxide. The clinical relevance of
the reduced loperamide plasma
concentration is unknown.
Fluticasone propionate In a clinical study where ritonavir Concomitant administration of
Interaction study 100 mg capsules bid were co- Aptivus, co-administered with
performed only with administered with 50 µg low dose ritonavir, and these
ritonavir intranasal fluticasone propionate glucocorticoids is not
(4 times daily) for 7 days in recommended unless the
healthy subjects, the fluticasone potential benefit of treatment
propionate plasma levels outweighs the risk of systemic
increased significantly, whereas corticosteroid effects (see
the intrinsic cortisol levels section 4.4). A dose reduction of
decreased by approximately 86% the glucocorticoid should be
(90% confidence interval considered with close monitoring
82-89%). Greater effects may be of local and systemic effects or a
expected when fluticasone switch to a glucocorticoid, which
propionate is inhaled. Systemic is not a substrate for CYP3A4
corticosteroid effects including (e.g. beclomethasone). Moreover,
Cushing’s syndrome and adrenal in case of withdrawal of
suppression have been reported in glucocorticoids progressive dose
patients receiving ritonavir and reduction may have to be
inhaled or intranasally performed over a longer period.
administered fluticasone The effects of high fluticasone
propionate; this could also occur systemic exposure on ritonavir
with other corticosteroids plasma levels are as yet
metabolised via the P450 3A unknown.
pathway e.g. budesonide.
It is unknown whether the
combination of tipranavir with
ritonavir might cause a larger
increase in fluticasone exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) loperamide (HOS-114855) budesonide (HOS-086332) propionate (HOS-108915) ritonavir (HOS-084521) beclomethasone (HOS-086334)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 7522c1a17dc381755410649aa6db82293f9c200ad2f0eeed696045d4a966abe6 · Zeichen 60402–64824 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 19–20
HOS-116394 · Präparat HOS-094447
19
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of
expected to increase these antipsychotic boosted PREZISTA and quetiapine
plasma concentrations. is contraindicated as it may
(CYP3A inhibition) increase quetiapine-related
toxicity. Increased concentrations
of quetiapine may lead to coma
(see section 4.3).
Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for
Risperidone expected to increase these antipsychotic these drugs when co-administered
Thioridazine plasma concentrations. with boosted PREZISTA.
(CYP3A, CYP2D6 and/or P-gp
Lurasidone inhibition) Concomitant administration of
Pimozide boosted PREZISTA and
Sertindole lurasidone, pimozide or sertindole
is contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is
Metoprolol expected to increase these β-blocker recommended when
Timolol plasma concentrations. co-administering boosted
(CYP2D6 inhibition) PREZISTA with β-blockers. A
lower dose of the β-blocker should
be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic
Diltiazem expected to increase the plasma and adverse effects is
Felodipine concentrations of calcium channel recommended when these
Nicardipine blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted
Verapamil PREZISTA.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted
metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all
(including were co-administered with 50 g routes of administration) that are
betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may
budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of
mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects,
triamcinolone) concentrations increased significantly, including Cushing’s syndrome and
whereas the intrinsic cortisol levels adrenal suppression.
decreased by approximately 86% (90%
CI 82-89%). Greater effects may be Co-administration with CYP3A-
expected when fluticasone is inhaled. metabolised corticosteroids is not
Systemic corticosteroid effects including recommended unless the potential
Cushing’s syndrome and adrenal benefit to the patient outweighs the
suppression have been reported in risk, in which case patients should
patients receiving ritonavir and inhaled or be monitored for systemic
intranasally administered fluticasone. The corticosteroid effects.
effects of high fluticasone systemic
exposure on ritonavir plasma levels are Alternative corticosteroids which
unknown. are less dependent on CYP3A
metabolism e.g. beclomethasone
Other corticosteroids: interaction not should be considered, particularly
studied. Plasma concentrations of these for long term use.
medicinal products may be increased
when co-administered with boosted
PREZISTA, resulting in reduced serum
cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with boosted
(CYP3A induction) PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) lead (HOS-085592) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 06bb26e6737c57cc3c74485aceb2076b3feb5ff5bad566ac99081f05e0924029 · Zeichen 52002–57572 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61–62
HOS-116527 · Präparat HOS-094447
61
Perphenazine Not studied. PREZISTA is expected to A dose decrease may be needed for
Risperidone increase these antipsychotic plasma these drugs when co-administered
Thioridazine concentrations. with PREZISTA co-administered
(CYP3A, CYP2D6 and/or P-gp with low dose ritonavir.
inhibition)
Lurasidone Concomitant administration of
Pimozide PREZISTA with low dose
Sertindole ritonavir and lurasidone, pimozide
or sertindole is contraindicated
(see section 4.3).
β-BLOCKERS
Carvedilol Not studied. PREZISTA is expected to Clinical monitoring is
Metoprolol increase these β-blocker plasma recommended when
Timolol concentrations. co-administering PREZISTA with
(CYP2D6 inhibition) β-blockers. A lower dose of the
β-blocker should be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. PREZISTA co-administered Clinical monitoring of therapeutic
Diltiazem with low dose ritonavir can be expected and adverse effects is
Felodipine to increase the plasma concentrations of recommended when these
Nicardipine calcium channel blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with PREZISTA with
Verapamil low dose ritonavir.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of PREZISTA
metabolised by CYP3A ritonavir 100 mg capsules twice daily with low dose ritonavir and
(including were co-administered with 50 g corticosteroids (all routes of
betamethasone, intranasal fluticasone propionate (4 times administration) that are
budesonide, fluticasone, daily) for 7 days in healthy subjects, metabolised by CYP3A may
mometasone, prednisone, fluticasone propionate plasma increase the risk of development of
triamcinolone) concentrations increased significantly, systemic corticosteroid effects,
whereas the intrinsic cortisol levels including Cushing’s syndrome and
decreased by approximately 86% (90% adrenal suppression.
CI 82-89%). Greater effects may be
expected when fluticasone is inhaled. Co-administration with CYP3A-
Systemic corticosteroid effects including metabolised corticosteroids is not
Cushing’s syndrome and adrenal recommended unless the potential
suppression have been reported in benefit to the patient outweighs the
patients receiving ritonavir and inhaled or risk, in which case patients should
intranasally administered fluticasone. The be monitored for systemic
effects of high fluticasone systemic corticosteroid effects.
exposure on ritonavir plasma levels are
unknown. Alternative corticosteroids which
are less dependent on CYP3A
Other corticosteroids: interaction not metabolism e.g. beclomethasone
studied. Plasma concentrations of these should be considered, particularly
medicinal products may be increased for long term use.
when co-administered with PREZISTA
with low dose ritonavir, resulting in
reduced serum cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with PREZISTA
(CYP3A induction) co-administered with low dose
ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 8b9ea54ec289adeef1a2f9f81165d44d84f0b8d5433cec6f77b7df8c89fd8286 · Zeichen 43290–48378 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 101–102
HOS-116617 · Präparat HOS-094447
101
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of
expected to increase these antipsychotic boosted PREZISTA and quetiapine
plasma concentrations. is contraindicated as it may
(CYP3A inhibition) increase quetiapine-related
toxicity. Increased concentrations
of quetiapine may lead to coma
(see section 4.3).
Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for
Risperidone expected to increase these antipsychotic these drugs when co-administered
Thioridazine plasma concentrations. with boosted PREZISTA.
(CYP3A, CYP2D6 and/or P-gp
Lurasidone inhibition) Concomitant administration of
Pimozide boosted PREZISTA and
Sertindole lurasidone, pimozide or sertindole
is contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is
Metoprolol expected to increase these β-blocker recommended when
Timolol plasma concentrations. co-administering boosted
(CYP2D6 inhibition) PREZISTA with β-blockers. A
lower dose of the β-blocker should
be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic
Diltiazem expected to increase the plasma and adverse effects is
Felodipine concentrations of calcium channel recommended when these
Nicardipine blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted
Verapamil PREZISTA.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted
metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all
(including were co-administered with 50 g routes of administration) that are
betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may
budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of
mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects,
triamcinolone) concentrations increased significantly, including Cushing’s syndrome and
whereas the intrinsic cortisol levels adrenal suppression.
decreased by approximately 86% (90%
CI 82-89%). Greater effects may be Co-administration with CYP3A-
expected when fluticasone is inhaled. metabolised corticosteroids is not
Systemic corticosteroid effects including recommended unless the potential
Cushing’s syndrome and adrenal benefit to the patient outweighs the
suppression have been reported in risk, in which case patients should
patients receiving ritonavir and inhaled or be monitored for systemic
intranasally administered fluticasone. The corticosteroid effects.
effects of high fluticasone systemic
exposure on ritonavir plasma levels are Alternative corticosteroids which
unknown. are less dependent on CYP3A
metabolism e.g. beclomethasone
Other corticosteroids: interaction not should be considered, particularly
studied. Plasma concentrations of these for long term use.
medicinal products may be increased
when co-administered with boosted
PREZISTA, resulting in reduced serum
cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with boosted
(CYP3A induction) PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) lead (HOS-085592) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage ccb6e0bf9fbd4db134b19a5c68f5c32c6656fffa35e00c9b9b966f86c2226743 · Zeichen 51473–57044 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-133976 · Präparat HOS-097520
Co-administration with
CYP3A-metabolised corticosteroids
is not recommended unless the
potential benefit to the patient
outweighs the risk, in which case
patients should be monitored for
systemic corticosteroid effects.
Alternative corticosteroids which
are less dependent on CYP3A
metabolism e.g. beclomethasone for
intranasal or inhalational use should
be considered, particularly for
long-term use.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): beclomethasone (HOS-086334)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 7e31834f5bc829102356f5281ff23d1b314f2d22ba45f25c27288c326412703c · Zeichen 22219–23484 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17–18
HOS-134507 · Präparat HOS-097580
17
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
Perphenazine Not studied. Darunavir is expected to A dose decrease may be needed for
Risperidone increase these antipsychotic plasma these drugs when co-administered
Thioridazine concentrations. with darunavir co-administered with
(CYP3A, CYP2D6 and/or P-gp low dose ritonavir.
inhibition)
Lurasidone Pimozide Concomitant administration of
Sertindole darunavir with low dose ritonavir
and lurasidone, pimozide or
sertindole is contraindicated (see
section 4.3).
β-BLOCKERS
Carvedilol Not studied. Darunavir is expected to Clinical monitoring is
Metoprolol increase these β-blocker plasma recommended when co-
Timolol concentrations. administering darunavir with β-
(CYP2D6 inhibition) blockers. A lower dose of the β-
blocker should be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Darunavir co-administered Clinical monitoring of therapeutic
Diltiazem with low dose ritonavir can be and adverse effects is recommended
Felodipine expected to increase the plasma when these medicines are
Nicardipine concentrations of calcium channel concomitantly administered with
Nifedipine blockers. darunavir with low dose ritonavir.
Verapamil (CYP3A and/or CYP2D6 inhibition)
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of darunavir with
metabolised by CYP3A ritonavir 100 mg capsules twice daily low dose ritonavir and
(including betamethasone, were co-administered with 50 μg corticosteroids (all routes of
budesonide, fluticasone, intranasal fluticasone propionate (4 administration) that are metabolised
mometasone, prednisone, times daily) for 7 days in healthy by CYP3A may increase the risk of
triamcinolone) subjects, fluticasone propionate plasma development of systemic
concentrations increased significantly, corticosteroid effects, including
whereas the intrinsic cortisol levels Cushing’s syndrome and adrenal
decreased by approximately 86% (90% suppression.
CI 82-89%). Greater effects may be
expected when fluticasone is inhaled. Co-administration with CYP3A-
Systemic corticosteroid effects metabolised corticosteroids is not
including Cushing’s syndrome and recommended unless the potential
adrenal suppression have been reported benefit to the patient outweighs the
in patients receiving ritonavir and risk, in which case patients should
inhaled or intranasally administered be monitored for systemic
fluticasone. The effects of high corticosteroid effects.
fluticasone systemic exposure on
ritonavir plasma levels are unknown. Alternative corticosteroids which
are less dependent on CYP3A
Other corticosteroids: interaction not metabolism e.g. beclomethasone
studied. Plasma concentrations of these should be considered, particularly
medicinal products may be increased for long term use.
when co-administered with darunavir
with low dose ritonavir, resulting in
reduced serum cortisol concentrations.
Dexamethasone (systemic) Not studied. Dexamethasone may Systemic dexamethasone should be
decrease plasma concentrations of used with caution when combined
darunavir. (CYP3A induction) with darunavir co-administered with
low dose ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 4d699252eaa8e454816efcf834725c875d4dc8037df504e7418d309238a96785 · Zeichen 43154–48076 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-134627 · Präparat HOS-097580
59
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
Perphenazine Not studied. Boosted darunavir is A dose decrease may be needed for
Risperidone expected to increase these these drugs when co-administered
Thioridazine antipsychotic plasma with boosted darunavir.
concentrations. (CYP3A, CYP2D6
and/or P-gp inhibition)
Lurasidone Concomitant administration of
Pimozide boosted darunavir and lurasidone,
Sertindole pimozide or sertindole is
contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted darunavir is Clinical monitoring is recommended
Metoprolol expected to increase these β-blocker when co-administering boosted
Timolol plasma concentrations. darunavir with β-blockers. A lower
(CYP2D6 inhibition) dose of the β-blocker should be
considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted darunavir can Clinical monitoring of therapeutic
Diltiazem be expected to increase the plasma and adverse effects is recommended
Felodipine concentrations of calcium channel when these medicines are
Nicardipine blockers. concomitantly administered with
Nifedipine (CYP3A and/or CYP2D6 boosted darunavir.
Verapamil inhibition)
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study Concomitant use of boosted
metabolised by CYP3A where ritonavir 100 mg capsules darunavir and corticosteroids (all
(including betamethasone, twice daily were co-administered routes of administration) that are
budesonide, fluticasone, with 50 μg intranasal fluticasone metabolised by CYP3A may increase
mometasone, prednisone, propionate (4 times daily) for 7 the risk of development of systemic
triamcinolone) days in healthy subjects, fluticasone corticosteroid effects, including
propionate plasma concentrations Cushing’s syndrome and adrenal
increased significantly, whereas the suppression.
intrinsic cortisol levels decreased
by approximately 86% (90% CI 82- Co-administration with CYP3A-
89%). Greater effects may be metabolised corticosteroids is not
expected when fluticasone is recommended unless the potential
inhaled. Systemic corticosteroid benefit to the patient outweighs the
effects including Cushing's risk, in which case patients should be
syndrome and adrenal suppression monitored for systemic corticosteroid
have been reported in patients effects.
receiving ritonavir and inhaled or
intranasally administered Alternative corticosteroids which are
fluticasone. The effects of high less dependent on CYP3A
fluticasone systemic exposure on metabolism
ritonavir plasma levels are e.g. beclomethasone should be
unknown. considered, particularly for long term
use.
Other corticosteroids: interaction
not studied. Plasma concentrations
of these medicinal products may be
increased when co-administered
with boosted darunavir, resulting in
reduced serum cortisol
concentrations.
Dexamethasone (systemic) Not studied. Dexamethasone may Systemic dexamethasone should be
decrease plasma concentrations of used with caution when combined
darunavir. with boosted darunavir.
(CYP3A induction)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) propionate (HOS-108915) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 5be93392fc9daddc5a4bddcaf5177effda2055057fdf350b6c14c2d3c31e17fc · Zeichen 49576–54404 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-138492 · Präparat HOS-098200
Alternative corticosteroids which
are less dependent on CYP3A
metabolism e.g. beclomethasone
should be considered, particularly
for long-term use.
Dexamethasone (systemic) Based on theoretical considerations Systemic dexamethasone should
(systemic) dexamethasone is be used with caution when
expected to decrease darunavir combined with Symtuza.
and/or cobicistat plasma
concentrations.
(CYP3A induction)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535) beclomethasone (HOS-086334)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage e5d46156e7a01f0e06f8b4f9a01190bdf1ac561213b5259437055e81ac828f8f · Zeichen 27605–28475 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.